Clinical Study of Carbon Ion Radiotherapy for Pancreatic Cancer.
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorGansu Wuwei Tumor Hospital
About this trial
The objective is to evaluate the efficacy and safety of carbon ion radiotherapy (CIRT) combined with nituzumab and gemcitabine in the treatment of locally advanced and metastatic pancreatic cancer.
Eligibility criteria
Qualifiers
Age ≥18 years and ≤80 years;
Indications: patients with locally advanced or metastatic pancreatic adenocarcinoma confirmed by histopathology or cytology (stage III - IV).
At least one measurable lesion was present according to RECIST version 1.1 evaluation criteria.
Suitable for one cycle of gemcitabine combined with nituzumab.
Disqualifiers
Patients who have received monoclonal antibodies, EGFR-TKI therapy, anti-angiogenic drugs, and immunosuppressants within six months.
Patients with uncontrolled, cancerous pleural effusion requiring frequent drainage, pericardial effusion, or ascites (allowing for cytological confirmation of effusion), gastrointestinal bleeding, or those identified by the investigator as having a high blood risk within 14 days prior to admission.
Participated in other interventional clinical trials within 30 days prior to screening.
The dose limit for organs at risk cannot reach the preset safe dose limit.
Trial design
Treatments tested in this trial
- carbon ion radiotherapy (CIRT)
Treatment groups
62 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov